MedTrace Logo

Saccharomyces Cerevisiae for Irritable Bowel Syndrome

NCT05149599 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-07

No results posted yet for this study

Summary

This study is designed to see the response of saccharomyces cerevisiae for symptomatic improvement of patients with IBS

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Saccharomyces cerevisiae

Saccharomyces cerevisiae, which is a pro-biotic, was given in capsule form, 500mg twice daily for 1 month

Sponsors & Collaborators

  • Hilton Pharma

    collaborator INDUSTRY

  • Ziauddin University

    lead OTHER

Principal Investigators

  • Mehreen Siyal, MBBS, FCPS-1 · DR ZIAUDDIN HOSPITAL, CLIFTON CAMPUS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05149599 on ClinicalTrials.gov